

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	6294231
<b>Application Number:</b>	10587426
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	8157
<b>Title of Invention:</b>	Treatment Of Neurodegenerative Diseases By The Use Of Atp7a
<b>First Named Inventor/Applicant Name:</b>	Carsten Hopf
<b>Customer Number:</b>	21559
<b>Filer:</b>	Forrester J. Liddle/Megan Kiley
<b>Filer Authorized By:</b>	Forrester J. Liddle
<b>Attorney Docket Number:</b>	50125/114001
<b>Receipt Date:</b>	22-OCT-2009
<b>Filing Date:</b>	26-JUN-2007
<b>Time Stamp:</b>	17:29:39
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	no
------------------------	----

### File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	NPL Documents	Treiber_et_al_Clioquinol_2004.pdf	317868 216448fb4e53d37d8a8f8808979f2b1e55ff389c	no	7

### Warnings:

### Information:

2	NPL Documents	Tuerk_et_al_PNAS_1992.pdf	1410090	no	6
			80548485e068350f4f55e7ab8714487f0fb4b875		
Warnings:					
Information:					
3	NPL Documents	Vassar_et_al_Science_1999.pdf	770035	no	7
			a0727ad6741e16396b9aa69adb12aed754e64235		
Warnings:					
Information:					
4	NPL Documents	Vely_et_al_Methods_MolBiol_2000.pdf	422807	no	9
			2d1bebccb42a51a6eab196c96a4aee94929cea75		
Warnings:					
Information:					
5	NPL Documents	Verhoeven_et_al_Science_1988.pdf	574584	no	3
			b73c7d88b4cc2168caeffca93e28f7596362caf6		
Warnings:					
Information:					
6	NPL Documents	Voskoboinik_et_al_BiochemBiophysResComm_2003.pdf	230945	no	7
			865430ae9b488256364db021ad90091cb7b7dc6f		
Warnings:					
Information:					
7	NPL Documents	Voskoboinik_JBiolChem_2001.pdf	408300	no	8
			b4b3ccaf40aea81648dee8af20456e32e6fc90e9		
Warnings:					
Information:					
8	NPL Documents	Winter_and_Milstein_Nature_1991.pdf	1785573	no	7
			45bfde074f034b7ec75a01bc409ae20dc2740cfb		
Warnings:					
Information:					
9	NPL Documents	Wood_et_al_Nature_1985.pdf	1209063	no	4
			578876c1bff86b8513eabc626a046eddf8af3790		
Warnings:					
Information:					
10	NPL Documents	Uhlmann_Chemical_Reviews_1990.PDF	6158123	no	42
			c4881d1eb2fb27d9f896f6f43bed222bf0091379		
Warnings:					
Information:					

11	NPL Documents	Vaish_Nucleic_Acids_Res_1998.PDF	810346	no	6
			141fd433210bf9fcc0a40211bc01be1a720aa9a1		
Warnings:					
Information:					
12	NPL Documents	Wilson_and_Nock_Curr_Opin_Chem_Biol_2002.PDF	606670	no	5
			400878f654ad561cfa5c2be7bc4bcf8c2169c485		
Warnings:					
Information:					
13	NPL Documents	Wu_and_Wu_J_Biol_Chem_1987.PDF	1059346	no	4
			765ba578de694fd20b61ec5cb0a6fe13720fd282		
Warnings:					
Information:					
14	NPL Documents	Yacyshyn_Gastroentology_1998.PDF	1322775	no	10
			d03a2d328fb6ff7f7b51ded38d8ba56acbe96b5		
Warnings:					
Information:					
15	NPL Documents	Yan_et_al_Nature_1999.pdf	373337	no	5
			722fbd34827a3dcb3c13be132b81bbe8212c6e96		
Warnings:					
Information:					
16	NPL Documents	Yu_et_al_J_Biol_Chem_1998.pdf	419220	no	6
			40d3b0e6ac1d13a40d6c329e92150d316f163792		
Warnings:					
Information:					
17	NPL Documents	Yu_et_al_Nature_2000.pdf	387746	no	7
			605bfe40eab2ee840daa51aefbdf5c03c89a738		
Warnings:					
Information:					
18	NPL Documents	Zheng_Kemeny_Clin_Exp_Immunol_1995.pdf	394366	no	3
			58d93e3fc22a141d64fc69812955ec9420aadba9		
Warnings:					
Information:					
19	NPL Documents	Zon_Pharma_Res_1988.pdf	1266148	no	11
			c63c625976f649e4505ef01657aa428da2878c5c		
Warnings:					
Information:					

20	NPL Documents	Waggoner_Neurobiology_Disease_1999.PDF	1335005 24394cd145af252624c69bd672639a28e339e432	no	10
<b>Warnings:</b>					
<b>Information:</b>					
21	NPL Documents	Vulpe_Nat_Genet_1993.PDF	1267738 d2687b5b64c359e2a9b0c26efa9055182ddde90f5	no	7
<b>Warnings:</b>					
<b>Information:</b>					
22	NPL Documents	Yamamoto_Cell_1980.PDF	2158414 96a2f2e876d45cdcd8d6cd88f85e81187831dd44	no	11
<b>Warnings:</b>					
<b>Information:</b>					
23	NPL Documents	Yu_Cell_1994.PDF	1546380 1e608a78871062f550f156f81f46cd27730c85999	no	13
<b>Warnings:</b>					
<b>Information:</b>					
24	NPL Documents	Wagner_et_al_PNAS_1981.pdf	1198983 40b8c23df9ee1f895e8ea438374790c422a4b3a2	no	5
<b>Warnings:</b>					
<b>Information:</b>					
25	NPL Documents	Xia_et_al_PNAS_1997.pdf	322128 cecc2595500f1259a52932b279ac9b4ee3b91c0e	no	6
<b>Warnings:</b>					
<b>Information:</b>					
26	NPL Documents	Vaughan_Nat_Biotech_1996.PDF	935946 0f3ae0bad7f6d10e4a2d64c9c618569d38c137f2	no	6
<b>Warnings:</b>					
<b>Information:</b>					
27	NPL Documents	Weinberger_et_al_Pharmacogenomics_2000.pdf	2174415 3b294140580f84e038ff9f478a2fee5a73c82f9f	no	22
<b>Warnings:</b>					
<b>Information:</b>					
28	Transmittal Letter	50125_114001_IDS.PDF	64169 5435ad3c941778816063b9980213c1a5b5b31ace	no	2
<b>Warnings:</b>					
<b>Information:</b>					

29	Foreign Reference	CA_2381952.PDF	2464190 034136f8a730bbdab44a608425bff59edf4b5012	no	37
<b>Warnings:</b>					
<b>Information:</b>					
30	Information Disclosure Statement (IDS) Filed (SB/08)	50125_114001_1449.PDF	993831 5bdbbf17ce48f93955a0524920ccae6412dfa361	no	14
<b>Warnings:</b>					
<b>Information:</b>					
This is not an USPTO supplied IDS fillable form					
<b>Total Files Size (in bytes):</b>			34388541		
<p><b>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</b></p> <p><b><u>New Applications Under 35 U.S.C. 111</u></b>  If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><b><u>National Stage of an International Application under 35 U.S.C. 371</u></b>  If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><b><u>New International Application Filed with the USPTO as a Receiving Office</u></b>  If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					